沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

农历年初三休市 02-16 12:08:06

6.130

-0.070

-1.13%

最高6.290	最低6.050	成交量18.30万
今开6.050	昨收6.200	日振幅3.87%
总市值41.19亿	流通市值41.19亿	总股本6.72亿
成交额113.12万	换手率0.03%	流通股本6.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":6.13,"timestamp":1771214886007,"preClose":6.2,"halted":0,"volume":183000,"delay":0,"changeRate":-0.011290322580645207,"floatShares":672000000,"shares":672000000,"eps":-0.338431,"marketStatus":"农历年初三休市","change":-0.07,"latestTime":"02-16 12:08:06","open":6.05,"high":6.29,"low":6.05,"amount":1131170,"amplitude":0.03871,"askPrice":6.13,"askSize":3000,"bidPrice":6.12,"bidSize":23000,"shortable":3,"etf":0,"ttmEps":-0.372288,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":6.2,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0.7400735296294333,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996/wiki","defaultTab":"wiki","newsList":[{"id":"2611170422","title":"港股异动 | 微创心通-B(02160)涨超6% 植入式心律转复除颤器进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2611170422","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611170422?lang=zh_cn&edition=full","pubTime":"2026-02-16 11:27","pubTimestamp":1771212433,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，微创心通-B涨超6%，截至发稿，涨6.33%，报0.84港元，成交额859.92万港元。消息面上，2月13日晚，微创心通发布公告称，近日，国家药品监督管理局“NMPA”医疗器械技术审评中心发布《创新医疗器械特别审查申请审查结果公示》，拟同意集团旗下新一代植入式心律转复除颤器TILEN/EYLEN 进入创新医疗器械特别审查程序。据此 ，TILEN/EYLEN有望成为国内首款获批的具备自主知识产权的磁共振条件安全ICD。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09996","BK1574","159883","VT","BK4585","BK4588","VXUS","BK1222","BK1583","BK1100","09997","02160"],"gpt_icon":0},{"id":"2611651851","title":"微创心通-B(02160)：植入式心律转复除颤器进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2611651851","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611651851?lang=zh_cn&edition=full","pubTime":"2026-02-13 23:03","pubTimestamp":1770994990,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微创心通-B 发布公告，近日，国家药品监督管理局“NMPA”医疗器械技术审评中心发布《创新医疗器械特别审查申请审查结果公示》，拟同意集团旗下新一代植入式心律转复除颤器TILEN/EYLEN 进入创新医疗器械特别审查程序。此次TILEN/EYLEN进入NMPA绿色通道，有望加速磁共振条件安全ICD的国产化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09997","BK1222","BK1100","02160","09996","BK1583","159883"],"gpt_icon":0},{"id":"2611813478","title":"中生北控生物科技(08247)附属中生医疗自主研发的BioCyte 系列流式细胞仪获发马来西亚医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2611813478","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611813478?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:43","pubTimestamp":1770972201,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中生北控生物科技 发布公告，本公司的附属公司中生(苏州)医疗科技有限公司自主研发的BioCyte 系列流式细胞仪，近日成功通过马来西亚医疗器械管理局的审核，正式获得马来西亚医疗器械注册证，注册编号为IVDA9463526–225393。BioCyte系列流式细胞仪凭藉稳定性能及检测准确性，已在国内市场获得应用。中生医疗依据当地相关法规要求，完成产品检测、技术资料提交及审核程式，最终获得马来西亚医疗器械管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1574","159883","BK1100","BK1583","08247","09997","BK1161","BK1222","159891"],"gpt_icon":0},{"id":"2611313360","title":"心力衰竭医疗器械开发商BioVentrix(BVXX.US)申请在美IPO 拟募资1700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611313360","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611313360?lang=zh_cn&edition=full","pubTime":"2026-02-13 14:57","pubTimestamp":1770965856,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于研发心力衰竭微创治疗技术的医疗器械公司BioVentrix于周四向美国证券交易委员会提交申请，拟通过首次公开募股筹集至多1700万美元资金。BioVentrix是一家研发并商业化用于治疗射血分数降低型心力衰竭的医疗器械公司。BioVentrix此前曾通过销售Revivent TC经导管心室增强系统获得收入，该产品已于2023年停止销售以节约资金。BioVentrix已于2025年8月5日秘密提交上市申请。本次IPO由The Benchmark Company独家担任账簿管理人，暂未披露发行定价条款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","159883","09997","BK1574","BK1222","09996","BK1583"],"gpt_icon":0},{"id":"2610956825","title":"每日卖空追踪 | 沛嘉医疗-B 02月11日卖空量成交9000股，卖空比例为1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610956825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610956825?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798646,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B北京时间02月11日，跌2.17%，卖空量成交9000股，较上一交易日减少75.68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163632a6ee20e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163632a6ee20e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1583","BK1574","BK1100"],"gpt_icon":0},{"id":"2610956840","title":"沛嘉医疗-B02月11日主力净流出80.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2610956840","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610956840?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:15","pubTimestamp":1770797747,"startTime":"0","endTime":"0","summary":"02月11日, 沛嘉医疗-B股价跌2.17%，报收6.30元，成交金额453.5万元，换手率0.11%，振幅4.50%，量比1.15。沛嘉医疗-B今日主力资金净流出80.1万元，上一交易日主力净流出0万元。该股近5个交易日下跌2.33%，主力资金累计净流出34.6万元；近20日主力资金累计净流出543.7万元，其中净流出天数为9日。该股主力净额占比0.02%，港股市场排名2531/2717。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211161952a6ee0ce8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211161952a6ee0ce8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1100","09996","BK1583"],"gpt_icon":0},{"id":"2610073856","title":"创新放量，交易升温！中国创新医疗器械发展迈入新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2610073856","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610073856?lang=zh_cn&edition=full","pubTime":"2026-02-11 09:54","pubTimestamp":1770774857,"startTime":"0","endTime":"0","summary":"在国家的大力支持下，我国创新医疗器械在近年来发展正突飞猛进。此外，2025年国家药监局公告进入创新医疗器械特别审查程序的产品数量也已高达122款，相比2024年接近翻倍。值得一提的是，随着国产医疗器械创新能力的不断提升，近两年来，中国创新医疗器械收购交易也正逐渐起势。总的来说，中国创新医疗器械产业正处在由大向强转变、换道超车的重要关口期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211095929a495c7e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211095929a495c7e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1222","BK1100","BK1587","09997","02190","09996"],"gpt_icon":0},{"id":"2610678139","title":"每日卖空追踪 | 沛嘉医疗-B 02月10日卖空量成交6000股，卖空比例为1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610678139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610678139?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:30","pubTimestamp":1770712245,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B北京时间02月10日，涨0.63%，卖空量成交6000股，较上一交易日减少93.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163629a492bd72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163629a492bd72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1100","BK1583","BK1574"],"gpt_icon":0},{"id":"2610832633","title":"广西北海市开展春节前医疗器械监督检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2610832633","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610832633?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:51","pubTimestamp":1770627060,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 春节将至，为切实保障群众节日期间用械安全，规范医疗器械市场秩序，近日，广西北海市市场监管部门开展春节前医疗器械质量安全监督检查行动，以强监管、严排查、守底线，守护群众健康过年。行动中，北海市市场监管部门坚持监管与服务并重，推动形成闭环管理。下一步，北海市市场监管部门将持续强化动态巡查，畅通投诉举报渠道，全力守护群众春节期间用械安全，保障人民群众度过平安祥和的新春佳节。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-09/doc-inhmfivm6305424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","BK1574","159883","BK1100","09997","BK1222","BK1583"],"gpt_icon":0},{"id":"2610800226","title":"九强生物最新公告：取得纤维蛋白（原）降解产物测定试剂盒医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610800226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610800226?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:43","pubTimestamp":1770626583,"startTime":"0","endTime":"0","summary":"九强生物公告称，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为纤维蛋白（原）降解产物测定试剂盒，注册证编号为京械注准20262400041，注册类别为Ⅱ类，有效期至2031年2月4日。该试剂盒用于体外定量检测人血浆中的纤维蛋白（原）降解产物含量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900020612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","09996","BK1222","BK0077","BK1100","BK0012","BK1574","BK0046","BK0028","BK1583","159883","BK0239","09997"],"gpt_icon":0},{"id":"2610027405","title":"海南自贸港医疗器械保税维修业务 首次实现全流程闭环","url":"https://stock-news.laohu8.com/highlight/detail?id=2610027405","media":"海口网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610027405?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:31","pubTimestamp":1770604260,"startTime":"0","endTime":"0","summary":"记者从海口海关获悉，近日，首批适用“执行例外措施”政策的区外保税维修货物已在海口国家高新区完成全部维修流程，并从海口美兰机场口岸复运出境，这标志着海南自贸港医疗器械保税维修业务首次实现“进口—维修—复运出境”全流程闭环。该项目允许企业在海关全程监管下，接收来自全球的自产待修医疗器械设备，开展检测、维修及功能升级服务，维修完成后直接复运出境。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-09/doc-inhmesxq2352301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1222","BK1583","BK1574","09997","159883","BK1100","09996"],"gpt_icon":0},{"id":"2610068865","title":"沛嘉医疗-B(09996)：提交GeminiOne® 经导管缘对缘修复系统的EU MDR CE标志注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2610068865","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610068865?lang=zh_cn&edition=full","pubTime":"2026-02-09 08:13","pubTimestamp":1770596006,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B 发布公告，公司已于近日正式提交用于治疗二尖瓣反流的GeminiOne经导管缘对缘修复系统的 EU MDR CE标志注册申请，HighLife SAS为其欧洲合作伙伴。提交CE标志注册申请意味着公司在推进全球化战略方面取得稳步进展。GeminiOne是公司内部研发的创新TEER装置。于本公告日期，GeminiOne的注册申请已获中华人民共和国国家药品监督管理局受理，并正在审评中。此外，GeminiOne已获美国食品药品监督管理局批准其临床试验用器械豁免，以开展早期可行性研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","09996","CE","BK1574","159891","EU","BK4585","BK4109","BK4588","BK4156","BK1583"],"gpt_icon":0},{"id":"2609526452","title":"开年两标 | 合景建设中标马来西亚医疗器械GMP洁净工程项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2609526452","media":"PCBworld","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609526452?lang=zh_cn&edition=full","pubTime":"2026-02-07 11:03","pubTimestamp":1770433408,"startTime":"0","endTime":"0","summary":"—— 2026 ——中标喜讯精益建设，以品质筑非凡2026年合景建设华章再启开年首月连中两标2月4日合景建设旗下海外公司洲际建设（马来西亚）有限公司成功中标国家重点高新技术企业新三板上市公司某医疗器械公司马来西亚新山工程项目续写中国工程企业在海外高端制造业建设领域的崭新篇章合景建设以“中国智慧”对话“全球市场”以“品质工程”服务“信任托付”助力制造业发展该公司是一家专注于临床医疗设备研发与制造的上","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020712480895403a8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020712480895403a8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","09996","03913","BK1574","BK1100","BK1229","BK1542","BK1222","BK1258","09997"],"gpt_icon":0},{"id":"2609255782","title":"沛嘉医疗-B盘中异动 早盘股价大跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609255782","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609255782?lang=zh_cn&edition=full","pubTime":"2026-02-06 10:00","pubTimestamp":1770343205,"startTime":"0","endTime":"0","summary":"2026年02月06日早盘10时00分，沛嘉医疗-B股票出现波动，股价急速跳水5.17%。截至发稿，该股报6.050港元/股，成交量13.9万股，换手率0.02%，振幅3.29%。沛嘉医疗-B股票所在的医疗设备及用品行业中，整体跌幅为0.35%。沛嘉医疗-B公司简介：沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020610000597a51d30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020610000597a51d30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","09996","BK1574","BK1100"],"gpt_icon":0},{"id":"2609020536","title":"【券商聚焦】中泰国际：政策继续支持高品质创新药与高端医疗器械","url":"https://stock-news.laohu8.com/highlight/detail?id=2609020536","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609020536?lang=zh_cn&edition=full","pubTime":"2026-02-06 08:40","pubTimestamp":1770338454,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际发布医药行业2月投资策略，生医疗保健指数1月上涨8.6%，跑赢恒生指数1.7个百分点，主因：1)CXO板块多家企业发布盈喜预告，推动股价上涨。3)国家医保局发布政策支持高品质手术机器人获溢价，医疗器械板块中相关个股上涨。该机构指，国家药监局继续支持高品质创新药发展。中国生物制药本身在肝病、自免、呼吸、肿瘤等领域已有丰富布局，本次通过收购将夯实心血管领域的竞争力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974664","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU0516422366.SGD","LU0456827905.SGD","09997","LU0516423174.USD","LU2125910500.SGD","BK1576","159883","SG9999002463.SGD","09996","LU0181495838.USD","159992","IE00BZ08YS42.EUR","02269","LU2045819591.USD","LU0348825331.USD","06978","BK1574","LU0043850808.USD","SG9999002562.SGD","LU0140636845.USD","LU0572944931.SGD","LU0320764599.SGD","01177","IE00BZ08YT58.USD","LU0039217434.USD","BK1191","LU0052750758.USD","03696","02359","BK1515","LU0307460666.USD","LU0516422952.EUR","LU0326950275.SGD","BK1610","LU0327786744.USD","HK0000165453.HKD","LU0516422440.USD","LU1242518857.USD","LU0708995583.HKD","IE00B0JY6N72.USD","LU0823426480.USD","LU0456846285.SGD","LU0359202008.SGD","BK1222","LU2039709279.SGD","LU0516423091.SGD","LU0348735423.USD","LU0417516738.SGD","LU0823426308.USD"],"gpt_icon":0},{"id":"2609533548","title":"沛嘉医疗-B(09996)发布2025年度业绩 实现收入约7亿元-7.2亿元 同比增长约13.7–17.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533548","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609533548?lang=zh_cn&edition=full","pubTime":"2026-02-06 07:21","pubTimestamp":1770333702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B 发布截至2025年12月31日止年度业绩，集团报告期间实现收入约人民币7亿元-7.2亿元，同比增长约13.7–17.0%。于报告期间，本集团已商业化的TAVR产品组合在约130间新医院中获采用，截至2025年12月31日已累计覆盖超过780间医院。于报告期间合计植入约3900台，按年增长14.4%，显著高于整体市场增长率。随着TaurusTrio经导管主动脉瓣系统的注册申请于2025年12月获国家药品监督管理局批准，本公司预期将于中国主动脉瓣反流市场展开全面商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1574","BK1583","159891","09996"],"gpt_icon":0},{"id":"2609309787","title":"明德生物（002932）披露增资并收购蓝怡（湖南）医疗器械有限公司股权进展公告，2月5日股价上涨0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309787","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309787?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:33","pubTimestamp":1770301993,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，明德生物报收于19.26元，较前一交易日上涨0.21%，最新总市值为44.78亿元。公告显示，公司于2026年1月19日召开第五届董事会第三次会议，审议通过增资并收购蓝怡（湖南）医疗器械有限公司股权的议案。截至本公告日，湖南蓝怡已完成工商变更登记，公司持有其51%股权，湖南蓝怡成为公司控股子公司，纳入合并报表范围。嘉善禾欣咨询管理合伙企业受让蓝怡集团持有的湖南蓝怡20%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","09997","BK1222","BK1100","159883","BK0239","09996","BK1574","002932"],"gpt_icon":0},{"id":"2609309733","title":"陇神戎发（300534）披露取得《医疗器械生产许可证》公告，2月5日股价下跌1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309733?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:27","pubTimestamp":1770301637,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，陇神戎发报收于10.21元，较前一交易日下跌1.64%，最新总市值为30.97亿元。陇神戎发于2026年2月5日发布《关于取得〈医疗器械生产许可证〉的公告》。公告显示，公司于2026年2月5日取得甘肃省药品监督管理局核发的《医疗器械生产许可证》，许可证编号为甘药监械生产许20260001号，生产范围为Ⅲ类：10-04-血液净化及腹膜透析器具，许可期限自2026年2月4日至2031年2月3日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK0132","300534","BK1583","BK0056","BK1574","BK1222","BK1100","09996","BK0239","09997"],"gpt_icon":0},{"id":"2609060093","title":"三鑫医疗（300453）披露控股子公司变更医疗器械生产许可证公告，2月5日股价上涨1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609060093","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609060093?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:17","pubTimestamp":1770301035,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，三鑫医疗报收于9.43元，较前一交易日上涨1.18%，最新总市值为49.23亿元。该股当日开盘9.28元，最高9.6元，最低9.26元，成交额达9887.11万元，换手率为2.9%。近日，三鑫医疗披露《关于控股子公司变更医疗器械生产许可证的公告》。公告显示，公司控股子公司成都威力生生物科技有限公司因生产经营需要，对其《医疗器械生产许可证》的生产地址进行了变更，并取得四川省药品监督管理局换发的新证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1222","300453","BK1583","09997","BK1100","159883","09996","BK0251"],"gpt_icon":0},{"id":"2609632216","title":"陇神戎发(300534.SZ)取得一项医疗器械生产许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2609632216","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609632216?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:41","pubTimestamp":1770280906,"startTime":"0","endTime":"0","summary":"智通财经APP讯，陇神戎发(300534.SZ)公告，公司取得由甘肃省药品监督管理局核发的《医疗器械生产许可证》，本次取得《医疗器械生产许可证》标志着公司血液透析浓缩液(干粉)产品具备生产和上市销售的资质。血液透析浓缩液(干粉)作为血液透析类医疗器械，用于急性肾衰竭、慢性肾衰竭的血液透析治疗，已经被临床广泛应用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","159883","BK1583","BK1574","BK0132","09997","BK1222","300534","BK0239","BK0056","BK1100"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":-0.0422},{"period":"1month","weight":-0.1354},{"period":"3month","weight":0.0869},{"period":"6month","weight":-0.2986},{"period":"1year","weight":0.4843},{"period":"ytd","weight":0.02}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0052},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0612},{"period":"1year","weight":0.1806},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.057115},{"month":2,"riseRate":0.5,"avgChangeRate":0.02105},{"month":3,"riseRate":0.4,"avgChangeRate":-0.110838},{"month":4,"riseRate":0.75,"avgChangeRate":0.044776},{"month":5,"riseRate":0.75,"avgChangeRate":-0.061692},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07739},{"month":7,"riseRate":0.5,"avgChangeRate":0.047595},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.086603},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.083675}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}